VI-0609: An Ethanol-Free Carmustine Formulation for Lymphoma Conditioning Therapy – A Comprehensive Review

1. Executive Summary

VI-0609 is an investigational, innovative, ethanol-free formulation of the alkylating agent carmustine, developed by VIVUS LLC. Its primary objective is to address the significant infusion-related toxicities associated with the conventional ethanol-containing carmustine formulation (BiCNU), particularly when used in high-dose chemotherapy regimens prior to autologous hematopoietic cell transplantation (AHCT) for patients with lymphoma. These toxicities, often attributed to the ethanol solvent, include facial pain, nausea, vomiting, and local irritation, contributing to patient burden and potentially limiting the rate of drug administration.

Currently, VI-0609 is undergoing a multicenter, randomized Phase 2 clinical trial (NCT06915246) where it is being compared directly to BiCNU within the standard BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) conditioning regimen for adult patients with relapsed or refractory Hodgkin or Non-Hodgkin lymphoma. The trial's primary endpoints focus on evaluating infusion-related toxicities within 24 hours post-infusion and unacceptable toxicities through Day 30 post-AHCT. Early reports suggest VI-0609 may utilize propylene glycol as an alternative solvent.

The anticipated benefits of VI-0609 include an improved safety and tolerability profile concerning infusion reactions, potentially allowing for shorter infusion times and thereby reducing patient discomfort and healthcare resource utilization. While VI-0609 aims to mitigate solvent-related adverse events, the intrinsic pharmacological properties and systemic toxicities of carmustine, such as myelosuppression and pulmonary toxicity, are expected to remain.

The development of VI-0609 exemplifies a strategic approach in pharmaceutical innovation focused on reformulating established therapeutic agents to enhance their clinical utility by improving safety and patient experience. This approach leverages the known efficacy of carmustine while addressing a specific, well-documented limitation of its current formulation. If the Phase 2 trial successfully demonstrates a favorable risk-benefit profile for VI-0609, particularly a reduction in infusion-related adverse events without compromising efficacy or introducing new significant toxicities, it could become a preferred carmustine formulation in lymphoma conditioning. The success of such a strategy could also encourage further exploration of solvent reformulation for other chemotherapeutic agents where excipients contribute to toxicity, potentially offering broader benefits to patients undergoing intensive cancer treatments.

2. Introduction to VI-0609: An Investigational Ethanol-Free Carmustine Formulation

2.1. Overview and Rationale for Development

VI-0609 is an investigational, small molecule drug representing an innovative, ethanol-free formulation of carmustine designed for intravenous injection.[1] Carmustine, the active pharmaceutical ingredient, is a well-established chemotherapeutic agent. The primary impetus for the development of VI-0609 stems from the desire to mitigate the infusion-related adverse events frequently associated with the conventional, ethanol-based formulation of carmustine, commercially known as BiCNU.[1] The ethanol solvent in BiCNU is implicated in a range of undesirable reactions, including facial pain, vomiting, flushing, and swelling of the tongue, which can cause significant patient discomfort and complicate treatment administration.[1]

By eliminating ethanol, VI-0609 is intended to offer an improved safety and tolerability profile, particularly during and immediately following infusion.[1] This improved tolerability is anticipated to translate into several clinical advantages, such as a reduction in the incidence and severity of infusion-related reactions and the potential for shorter drug infusion times compared to high-dose BiCNU.[1] Such improvements could substantially lessen the patient burden associated with high-dose conditioning therapy prior to autologous hematopoietic cell transplantation (AHCT), a critical treatment modality for certain hematologic malignancies.[1] While many sources confirm the "ethanol-free" nature of VI-0609, specific details from clinical trial information suggest that the formulation may utilize propylene glycol as an alternative solvent system.[7] The choice of propylene glycol would be a considered pharmacological decision, aiming to maintain carmustine solubility—given its poor water solubility [8]—while offering a potentially less toxic solvent profile than ethanol. The ongoing clinical trials are crucial for validating the safety and comparative tolerability of this specific propylene glycol-based carmustine formulation.

2.2. Developer: VIVUS LLC

VI-0609 has been developed by VIVUS LLC, a biopharmaceutical company headquartered in Campbell, California.[1] The company, also referred to as VIVUS, Inc. in some databases [2], is committed to the development and commercialization of innovative therapies targeting serious unmet medical needs.[1] VIVUS's portfolio extends beyond oncology, with marketed products such as QSYMIA® for chronic weight management and PANCREAZE® for exocrine pancreatic insufficiency.[2] The development of VI-0609 for bone marrow transplant preparation signifies an active expansion or diversification of VIVUS's pipeline into the oncology space.[2]

This strategic move into oncology with a reformulated product like VI-0609, rather than a novel molecular entity, may reflect an approach to leverage the established efficacy of an existing drug while addressing a clear clinical need for improved safety. The development of therapies for niche indications, such as conditioning regimens for AHCT, aligns with VIVUS's stated mission of focusing on serious unmet medical needs. The relatively defined development pathway for a reformulated product, focusing on comparative safety and tolerability against an existing standard, might also present a more manageable entry into the complex field of oncology therapeutics for a company with primary expertise in other areas.

3. Pharmacology of Carmustine (Active Ingredient of VI-0609)

3.1. Mechanism of Action

Carmustine, also known as BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), is the active pharmaceutical ingredient in VI-0609. It is a highly lipid-soluble compound belonging to the nitrosourea class of chemotherapeutic agents.[8] Carmustine functions as a bifunctional alkylating agent.[9] Its primary mechanism involves the alkylation of DNA and RNA, leading to the formation of interstrand and intrastrand cross-links.[11] These cross-links interfere with DNA replication and transcription, ultimately inhibiting DNA synthesis, RNA production, and protein synthesis, which culminates in cell death.[12]

In addition to direct DNA and RNA damage, carmustine can also inhibit several key enzymatic processes through the carbamoylation of amino acids in proteins.[9] One notable target of carbamoylation is glutathione reductase, an enzyme crucial for cellular defense against oxidative stress; its inhibition can further sensitize cells to damage.[13] Carmustine is considered a cell-cycle phase non-specific agent, meaning it can exert its cytotoxic effects on cells regardless of their phase in the cell division cycle.[11] An important characteristic of carmustine is that it generally does not exhibit cross-resistance with other classes of alkylating agents, although cross-resistance with lomustine, another nitrosourea, has been reported.[9]

The fundamental cytotoxic mechanism of carmustine, centered on its alkylating and carbamoylating properties, will be inherent to VI-0609, as the active molecule remains unchanged. The reformulation to an ethanol-free preparation is designed to alter the delivery and immediate tolerability of the drug, not its intrinsic molecular interactions with cellular targets. Consequently, the efficacy profile and the spectrum of systemic (non-infusion-related) toxicities are anticipated to be similar between VI-0609 and ethanol-based carmustine formulations, assuming comparable systemic drug exposure is achieved.

3.2. Pharmacokinetics (based on IV Carmustine, BiCNU)

The pharmacokinetic profile of intravenously administered carmustine has been well-characterized:

• Absorption: For intravenous formulations like BiCNU and the investigational VI-0609, conventional absorption processes are bypassed, with the drug directly entering systemic circulation.[1] Bioavailability data for other routes, such as oral, are variable and less relevant here.[13]
• Distribution: Carmustine is highly lipid-soluble, a property that significantly influences its distribution.[8] It readily crosses the blood-brain barrier (BBB), achieving concentrations in the cerebrospinal fluid (CSF) that are reported to be 15-70% of concurrent plasma concentrations in adults.[9] This BBB penetration is a key factor in its efficacy against brain tumors but also contributes to its broad tissue distribution. Carmustine also enters breast milk.[11] The volume of distribution (Vd​) is approximately 3.25 L/kg.[11] Plasma protein binding is around 80%.[11] While the BBB penetration is critical for its use in neuro-oncology [8], its relevance in lymphoma conditioning for AHCT is primarily related to achieving systemic drug exposure for myeloablation. However, this widespread distribution also means that various organs can be exposed to carmustine, contributing to its systemic toxicity profile, which is unlikely to be altered by the ethanol-free formulation.
• Metabolism: Carmustine undergoes rapid and extensive metabolism. Intact drug is typically undetectable in plasma within 15 minutes of intravenous administration.[9] It is subject to both spontaneous chemical decomposition and significant hepatic metabolism, likely involving the cytochrome P450 (CYP) enzyme system.[11] This metabolic activity results in the formation of active metabolites, which may persist in the plasma for longer periods than the parent drug and contribute to its therapeutic and toxic effects.[11]
• Excretion: The elimination of carmustine and its metabolites occurs primarily through the kidneys, with approximately 60-70% of a total dose excreted in the urine within 96 hours.[9] A smaller fraction, around 6-10%, is excreted via the lungs as carbon dioxide.[11] Fecal excretion is minimal, accounting for less than 1% of the dose.[11]
• Half-life: The parent carmustine molecule has a short terminal half-life, reported as 0.25-0.75 hours (non-linear and dose-related) [11] or 15-30 minutes.[13] However, its active metabolites may have a more prolonged presence in the body.

The pharmacokinetic parameters of carmustine are not expected to be fundamentally altered by the change in formulation from ethanol-based to ethanol-free (e.g., propylene glycol-based), assuming the new formulation achieves comparable systemic exposure of the active drug.

4. Clinical Development Program for VI-0609

4.1. Overview of Clinical Trials

VI-0609 is currently in Phase 2 of clinical development, with a focus on its application in bone marrow transplant preparation.[1] While one VIVUS pipeline overview dated somewhat earlier indicated a Phase 1 status for VI-0609 in this indication [10], more recent and specific announcements regarding the active clinical trial NCT06915246 confirm its progression to Phase 2.[1] This trial is central to evaluating the clinical viability of VI-0609.

4.2. In-Depth Analysis of Phase 2 Trial NCT06915246 (also NCI-2025-02742, LY-201)

The pivotal study for VI-0609 is a Phase 2 clinical trial identified by the ClinicalTrials.gov identifier NCT06915246, and also referenced as NCI-2025-02742 and LY-201.[15]

• Study Title and Design: The trial is titled "A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma" or a similar variant, reflecting its core objective of assessing an ethanol-free carmustine formulation (VI-0609) against the standard ethanol-containing formulation (BiCNU).[1] It is a randomized, multicenter study.[1] Participants are randomized into two groups: one receiving carmustine with ethanol (BiCNU) and the other receiving carmustine with propylene glycol (presumed to be VI-0609).[7] This explicit mention of propylene glycol provides a strong indication of the solvent used in the VI-0609 formulation being tested.
• Primary Objectives: The primary objectives are designed to directly assess the hypothesized benefits of the ethanol-free formulation:

1. To evaluate infusion-related toxicities for VI-0609 versus BiCNU occurring within 24 hours post-infusion.[1] This timeframe is critical for capturing acute reactions linked to the solvent.
2. To evaluate unacceptable toxicities for VI-0609 versus BiCNU from the start of the BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) conditioning regimen through Day 30 post-AHCT.[1] This broader window allows for the assessment of other early post-transplant complications that might be influenced by the carmustine formulation. The selection of these endpoints underscores a pragmatic approach, focusing on the primary differentiator (infusion safety) while also ensuring a comprehensive early safety comparison in the context of an intensive multagent chemotherapy regimen.

• Patient Population and Key Eligibility Criteria: The study enrolls adult patients (≥ 18 years of age) with histologically confirmed Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL), specifically those with refractory or relapsed disease who are candidates for AHCT consolidation therapy.[1] Other key inclusion criteria include:
• Life expectancy of at least 6 months and a Karnofsky performance status of ≥ 70%.[15]
• Achievement of a complete or partial response to prior therapy before AHCT.[15]
• Successful collection of an adequate number of autologous hematopoietic progenitor cells (HPCs), defined as at least 2.0×106 CD34+ cells/kg of body weight.[15]
• Adequate organ function, including cardiac function (Left Ventricular Ejection Fraction, LVEF≥50%) and pulmonary function (Forced Expiratory Volume in 1 second, FEV1​>65% of predicted; Diffusing Capacity of the Lungs for Carbon Monoxide, DLCO≥50% of predicted).[15] The pulmonary function criteria are particularly noteworthy, reflecting the known risk of carmustine-induced pulmonary toxicity. These criteria aim to select patients who are more likely to tolerate this inherent risk, suggesting that VI-0609 is not primarily expected to mitigate carmustine's underlying pulmonary effects but rather to be non-inferior in this regard while improving infusion safety.
• Negative serology for HIV, active Hepatitis B or C, and syphilis.[15]
• Exclusion criteria include the use of other investigational medications, presence of myelodysplasia or other active malignancies, persistent bone marrow involvement by lymphoma after salvage therapy, insufficient stem cell harvest, and certain active viral infections.[15]
• Treatment Regimen: VI-0609 or BiCNU is administered as a component of the BEAM high-intensity conditioning regimen prior to AHCT.[1] The standard dose of carmustine within the BEAM regimen is typically 300 mg/m2 administered intravenously on day -6 of the transplant timeline.[17]
• Current Status and Participating Centers: The trial is actively recruiting participants.[7] The first patient was enrolled and dosed on April 14, 2025, at the City of Hope National Medical Center in Duarte, California.[1] Other participating City of Hope locations include sites in Goodyear, Arizona; Newnan, Georgia; and Zion, Illinois.[7]

The trial's design, comparing a propylene glycol-based carmustine formulation against the standard ethanol-based one, means the safety assessment will need to carefully distinguish between effects related to the absence of ethanol, potential effects of propylene glycol (which, while generally safer, can have its own toxicities at high doses or rapid infusion rates, such as hyperosmolality or lactic acidosis), and the background toxicities of carmustine itself.

5. Therapeutic Indications and Clinical Utility

5.1. Targeted Malignancies: Hodgkin and Non-Hodgkin Lymphoma

VI-0609 is specifically being investigated for use in patients with Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL).[1] The development program focuses on patients with refractory or relapsed forms of these lymphoid malignancies who are candidates for AHCT.[1] Carmustine (as BiCNU) already holds FDA approval for these indications, typically as a component of secondary therapy for patients who have relapsed or failed to respond to primary treatments.[8] Therefore, VI-0609 is not seeking to establish a new indication for carmustine but rather to provide an improved formulation for its existing use in this patient population.

5.2. Role in Autologous Hematopoietic Cell Transplantation (AHCT) Conditioning

The primary clinical utility envisioned for VI-0609 is as a component of high-dose chemotherapy conditioning regimens administered prior to AHCT.[1] The specific regimen highlighted in the clinical development of VI-0609 is BEAM (Carmustine, Etoposide, Cytarabine, Melphalan).[1] BEAM is a widely recognized and frequently utilized high-intensity conditioning regimen for lymphoma patients undergoing AHCT, designed to eradicate residual malignant cells and ablate the patient's bone marrow to allow for successful engraftment of transplanted hematopoietic stem cells.[3]

Conditioning regimens like BEAM are inherently intensive and associated with substantial toxicities that can significantly impact patient well-being and treatment outcomes.[1] VI-0609 aims to alleviate some of this burden by improving the tolerability of the carmustine component, which is often associated with acute infusion-related side effects.[1] By targeting the BEAM regimen, VIVUS is positioning VI-0609 for potential integration into an established standard of care. If the Phase 2 trial demonstrates improved safety and tolerability with at least non-inferior efficacy, VI-0609 could be adopted by transplant centers as a direct replacement for BiCNU within existing BEAM protocols. This straightforward substitution, without necessitating a complete overhaul of the conditioning regimen, could facilitate a relatively rapid uptake in clinical practice.

Furthermore, the focus on patients with "refractory or relapsed" lymphoma means VI-0609 is being evaluated in a population that has typically undergone multiple prior lines of therapy. Such patients may have diminished physiological reserves and heightened vulnerability to treatment-related toxicities. An improvement in the safety profile of a key conditioning agent like carmustine, even if primarily related to infusion reactions, could be particularly meaningful for this group. It could potentially lead to better overall tolerability of the AHCT process, reduced need for supportive care interventions, and an improved quality of life during a highly challenging treatment phase.

6. Comparative Profile: VI-0609 versus BiCNU (Ethanol-Containing Carmustine)

6.1. Anticipated Advantages of VI-0609: Focus on Safety and Tolerability

The central value proposition of VI-0609 lies in its potential to offer a superior safety and tolerability profile compared to the conventional ethanol-containing carmustine formulation, BiCNU. This advantage is primarily attributed to the elimination of ethanol as a solvent.[1] Ethanol in BiCNU is linked to a spectrum of infusion-related adverse events, including, but not limited to, facial pain, vomiting, swelling of the tongue, and flushing.[1] By being ethanol-free, VI-0609 is expected to significantly reduce the incidence and severity of these specific reactions, thereby improving the overall patient experience during carmustine administration.[1]

6.2. Potential for Shorter Infusion Times and Reduced Patient Burden

A corollary to improved infusion tolerability is the potential for VI-0609 to be administered over a shorter period compared to high-dose BiCNU.[1] The infusion rate of BiCNU is often limited by the need to manage ethanol-related side effects; for instance, a 300 mg/m2 dose in the BEAM regimen is typically infused over 3 hours.[17] If VI-0609 proves to be better tolerated during infusion, it might be possible to increase the administration rate, constrained only by the intrinsic pharmacology of carmustine or the tolerability of the alternative solvent (e.g., propylene glycol) at higher infusion speeds.

Shorter infusion times offer tangible benefits: they can reduce the overall time a patient needs to spend in the infusion suite, lessen patient discomfort and anxiety associated with prolonged infusions, and improve the operational efficiency of treatment centers by increasing patient throughput and optimizing resource allocation.[1] These practical and potential economic advantages could be strong drivers for the adoption of VI-0609, provided its safety and efficacy are confirmed.

6.3. The BEAM Regimen and the Role of Carmustine

The BEAM regimen is a cornerstone of conditioning therapy for lymphoma patients undergoing AHCT. It comprises:

• Bacillus Calmette-Guérin (BCG) - Note: This is a common misattribution. The 'B' in BEAM stands for BCNU (carmustine).
• Etoposide
• Ara-C (cytarabine)
• Melphalan

A standard BEAM protocol involves Carmustine at a dose of 300 mg/m2 IV on day -6 relative to stem cell infusion (Day 0). This is followed by Etoposide (e.g., 100-200 mg/m2 IV, often administered twice daily or daily for several days, such as days -5 to -2), Cytarabine (e.g., 100-200 mg/m2 IV twice daily, typically on days -5 to -2), and Melphalan (e.g., 140 mg/m2 IV on day -1).[17] Specific dosages and schedules can exhibit minor variations between institutions. Carmustine is the first chemotherapeutic agent administered in this sequence.

The following table provides a comparative overview based on available information and anticipated characteristics:

Table 1: Comparative Overview of Carmustine Formulations in BEAM Conditioning

Feature	BiCNU (Ethanol-based)	VI-0609 (Ethanol-free, Propylene Glycol-based - Expected/Hypothesized)
Solvent	Ethanol	Propylene Glycol (based on NCT06915246 trial design 7)
Standard Infusion Time (for 300 mg/m2)	Typically ≥ 2-3 hours 17	Potentially shorter, pending trial data
Common Infusion-Related Toxicities	Facial pain, flushing, local irritation/burning, nausea/vomiting (ethanol-induced), tongue swelling 1	Expected reduction/absence of ethanol-specific toxicities
Hypothesized Incidence of Infusion Reactions	Moderate to High	Low (for ethanol-related reactions)
Potential for Dose Rate-Limiting Infusion Toxicity	Yes, due to ethanol	Reduced for ethanol; potential new limits based on propylene glycol/carmustine
Patient-Reported Burden (Infusion Discomfort)	Can be significant	Expected to be lower
Logistical Considerations for Administration	Slow infusion often required; premedication for ethanol effects may be considered	Potentially faster infusion; standard premedication for carmustine

It is important to recognize that while the focus is on mitigating ethanol-related issues, the introduction of propylene glycol as a solvent in VI-0609 brings its own set of considerations. Propylene glycol is generally regarded as safe but is not inert. At high doses or with rapid infusion, it can be associated with adverse effects such as hyperosmolality, lactic acidosis, central nervous system depression, cardiotoxicity, and renal dysfunction. The substantial dose of carmustine used in BEAM regimens necessitates a considerable volume of solvent. Therefore, the clinical trial (NCT06915246) must meticulously evaluate the overall safety profile of the VI-0609 formulation to ensure that any new solvent-related issues do not offset the benefits gained from eliminating ethanol. The net clinical advantage will be determined by a comprehensive comparison of the complete safety profiles of both formulations.

7. Safety and Tolerability Profile (Derived from Carmustine and VI-0609 Clinical Data)

7.1. Known Adverse Reactions Associated with Carmustine (BiCNU) - Systemic Effects

Carmustine, as the active ingredient, is associated with a range of significant systemic toxicities, largely independent of the ethanol solvent in BiCNU. These are expected to be relevant for VI-0609 as well.

• Hematologic Toxicity (Myelosuppression): This is the most common and severe dose-limiting toxicity of carmustine.[8] It is characteristically delayed, with nadirs for thrombocytopenia and leukopenia typically occurring 4-6 weeks (or 21-35 days) after drug administration.[9] Myelosuppression is dose-related and cumulative with repeated courses.[8] Thrombocytopenia is often more pronounced than leukopenia, though both can lead to serious complications such as bleeding and severe infections.[8] Anemia may also occur but is generally less frequent and less severe.[11]
• Pulmonary Toxicity: Carmustine can cause dose-related pulmonary toxicity, which can be fatal.[8] It manifests as pulmonary infiltrates and/or fibrosis.[9] The risk is substantially increased with cumulative doses exceeding 1400 mg/m2, but toxicity has been reported at lower doses.[8] A particularly concerning aspect is delayed-onset pulmonary fibrosis, which can occur months or even years after treatment, especially in individuals treated during childhood or adolescence.[8]
• Gastrointestinal Effects: Nausea and vomiting are frequently observed, typically beginning within 2-4 hours of intravenous administration and lasting for 4-6 hours.[8] These symptoms can be severe and are dose-related. Other GI effects include anorexia, diarrhea, and stomatitis.[11]
• Hepatotoxicity: Reversible elevations in liver function tests (transaminases, alkaline phosphatase, bilirubin) have been reported in a percentage of patients.[8] In some cases, particularly with high-dose therapy, more severe liver injury such as cholestatic hepatitis or sinusoidal obstruction syndrome (veno-occlusive disease) can occur.[11]
• Nephrotoxicity: Renal abnormalities, including progressive azotemia, decreased kidney size, and renal failure, have been documented, particularly in patients receiving large cumulative doses of carmustine over prolonged periods.[8] Kidney damage has also been reported occasionally at lower total doses.
• Other Toxicities:
• Ocular toxicities: Reports include retinal hemorrhages and blurred vision.[11] Intra-arterial administration (off-label) has been associated with blindness.[19]
• Neurotoxicity: Encephalopathy, ataxia, and dizziness have been observed.[11]
• Secondary Malignancies: Long-term therapy with nitrosoureas, including carmustine, has been associated with the development of secondary malignancies such as acute leukemia and bone marrow dysplasias.[8]
• Local Reactions: Burning sensation at the injection site is common.[14] Accidental skin contact with reconstituted carmustine can cause burning and transient hyperpigmentation.[8]
• Ethanol-Related Effects (with BiCNU): Hypotension and intense flushing of the skin and conjunctiva are often attributed to the ethanol diluent, especially with rapid infusion.[8]

7.2. Contraindications and Precautions for Carmustine Use

The use of carmustine requires careful consideration of its contraindications and adherence to specific precautions:

• Contraindications: The primary contraindication is known hypersensitivity to carmustine or any of the ingredients in its formulation.[19]
• Boxed Warnings (for BiCNU, relevant to carmustine):
• Myelosuppression: Emphasizing the risk of severe, delayed, and cumulative bone marrow suppression, requiring close hematologic monitoring.[8]
• Pulmonary Toxicity: Highlighting the risk of dose-related, potentially fatal pulmonary toxicity, which can have a delayed onset.[8]
• Precautions:
• Monitoring: Weekly complete blood counts (CBCs) are essential during therapy and for at least 6 weeks after each dose due to delayed myelosuppression.[8] Baseline pulmonary function studies (including FVC and DLCO) should be conducted, with frequent monitoring during treatment, especially for patients with pre-existing lung disease or baseline values <70% of predicted.[8] Liver and renal function should also be monitored periodically.[8]
• Pregnancy and Fetal Harm: Carmustine is embryotoxic and teratogenic in animal studies. Women of childbearing potential should be advised to avoid pregnancy during therapy and for a period thereafter. If used during pregnancy, the patient should be apprised of the potential hazard to the fetus.[8]
• Nursing Mothers: It is not known if carmustine is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during carmustine therapy.[8]
• Pediatric Use: Carmustine should be used with extreme caution in children due to the high risk of severe and delayed pulmonary toxicity. Fatal pulmonary fibrosis occurring up to 17 years after treatment in childhood has been reported.[8]
• Carcinogenicity and Mutagenicity: Carmustine is carcinogenic in animal models and mutagenic in various assays. Nitrosourea therapy carries a carcinogenic potential in humans.[8]
• Fertility: Carmustine can impair fertility.[8]

7.3. Expected Safety Profile of VI-0609

The primary safety advantage anticipated for VI-0609 is the reduction or elimination of acute, infusion-related adverse events that are specifically linked to the ethanol content of BiCNU. These include facial pain, ethanol-induced vomiting, tongue swelling, and flushing directly attributable to the solvent.[1] This improvement in immediate tolerability is a key objective of its development.

However, the systemic toxicities inherent to the carmustine molecule itself—such as myelosuppression, pulmonary toxicity, nephrotoxicity, hepatotoxicity, and non-infusion-related gastrointestinal toxicity—are likely to persist with VI-0609, assuming comparable systemic exposure to carmustine. The Phase 2 trial (NCT06915246) is designed to capture data on "unacceptable toxicities" up to Day 30 post-AHCT, which will provide crucial information on the overall early safety profile of VI-0609 in the context of the BEAM regimen.[1]

A reduction in severe nausea and vomiting, if a component of these symptoms is directly related to ethanol during the infusion, could enhance patient compliance and comfort. This might also lessen the need for aggressive antiemetic premedication specifically targeted at the carmustine infusion itself. Nevertheless, because other components of the BEAM regimen (etoposide, cytarabine, melphalan) are also emetogenic [17], comprehensive antiemetic prophylaxis will remain essential for patients undergoing this conditioning therapy.

It is also possible that the alternative solvent system used in VI-0609 (presumed to be propylene glycol based on trial information [7]) could introduce its own, albeit potentially milder, infusion site reactions or systemic effects. The clinical trial will be essential in characterizing any such new toxicities and determining the net safety benefit of VI-0609 compared to BiCNU. The major long-term and cumulative toxicities of carmustine, especially delayed pulmonary fibrosis and profound myelosuppression, will likely remain significant concerns requiring the same diligent monitoring and precautions as with BiCNU, as these are tied to the pharmacology of the active drug rather than the solvent.

8. Drug Interactions (Relevant to Carmustine)

Carmustine's metabolism, primarily hepatic and involving the cytochrome P450 (CYP) system [12], along with its effects on rapidly dividing cells and potential for organ toxicity, predisposes it to several drug interactions. These interactions are relevant to VI-0609 as the active drug remains carmustine.

• Cimetidine: Co-administration of cimetidine has been reported to increase the myelosuppressive activity of carmustine.[8] This interaction is particularly relevant as patients undergoing intensive chemotherapy often receive H2-receptor antagonists or proton pump inhibitors for gastrointestinal protection or management of dyspepsia. Awareness of this specific interaction is crucial for clinicians to either select alternative acid-suppressing agents or intensify hematologic monitoring if cimetidine use is unavoidable.
• Phenytoin and Fosphenytoin: Carmustine may decrease the serum concentrations of phenytoin and its prodrug fosphenytoin, potentially reducing their efficacy.[13]
• Phenobarbital: Phenobarbital is listed as a potentially interacting drug [21], likely due to its potent induction of CYP enzymes, which could alter carmustine metabolism, though specifics are not detailed in the provided material.
• Other Myelosuppressive or Immunosuppressive Agents: Additive hematologic toxicity and immunosuppression are significant concerns when carmustine is used with other chemotherapeutic agents (such as those in the BEAM regimen) or other immunosuppressive drugs (e.g., corticosteroids like betamethasone [13]). This necessitates careful monitoring and potential dose adjustments.
• Vaccines: Due to its immunosuppressive effects, carmustine can reduce the efficacy of both live and inactivated vaccines.[23] Live vaccines should generally be avoided during and for a period after carmustine therapy due to the risk of disseminated infections.
• Drugs Affecting Carmustine Metabolism or Excretion:
• Carmustine may decrease the excretion rate of a multitude of other drugs, potentially leading to their increased serum levels and associated toxicities. An extensive list of such potential interactions is documented in databases like DrugBank.[13] While the clinical significance of many of these is not established, the breadth of these interactions suggests carmustine may act as an inhibitor of certain drug elimination pathways.
• Conversely, certain drugs might increase the excretion rate of carmustine, potentially reducing its efficacy.[13]
• As carmustine is metabolized by CYP enzymes, co-administration with strong inhibitors or inducers of relevant CYP isoforms could theoretically alter carmustine plasma concentrations, though the specific isoforms critically involved in carmustine metabolism are not fully elucidated in the provided materials.

The extensive list of potential interactions, particularly those where carmustine may decrease the excretion of other drugs, underscores the importance of a thorough medication review for any patient scheduled to receive carmustine. The change in formulation to VI-0609 is unlikely to alter these systemic drug interaction potentials, as they are primarily related to the carmustine molecule itself and its effects on metabolic enzymes or transporter systems.

Table 2: Selected Clinically Significant or Potential Drug Interactions with Carmustine

Interacting Drug/Class	Potential Effect with Carmustine	Management/Clinical Implication
Cimetidine	Increased myelosuppressive activity of carmustine 8	Avoid co-administration if possible; if used, monitor hematologic parameters very closely. Consider alternative acid suppressants.
Phenytoin / Fosphenytoin	Decreased serum concentrations of phenytoin/fosphenytoin 13	Monitor phenytoin levels closely and adjust dosage as needed to maintain therapeutic concentrations.
Phenobarbital	Potential alteration of carmustine metabolism (likely induction) 21	Monitor for altered carmustine efficacy or toxicity if co-administered; consider alternatives to phenobarbital if possible.
Other Myelosuppressive Agents (e.g., etoposide, cytarabine, melphalan in BEAM)	Additive or synergistic myelosuppression	Expected interaction in combination chemotherapy; monitor hematologic parameters vigilantly; dose adjustments based on toxicity.
Live Vaccines	Decreased vaccine efficacy; risk of disseminated infection 23	Avoid co-administration. Defer live vaccinations until immune recovery.
Inactivated Vaccines	Decreased vaccine efficacy 23	Administer vaccines prior to chemotherapy if possible; revaccination may be necessary post-treatment depending on immune response.
Drugs with Renal Excretion Inhibited by Carmustine (Numerous examples in 13)	Increased serum levels and potential toxicity of the co-administered drug	Thorough medication review is essential. For critical narrow therapeutic index drugs, consider monitoring their levels or for signs of increased toxicity.
Palifermin	Increased toxicity of carmustine if administered within 24 hours 23	Do not administer palifermin within 24 hours before, during, or 24 hours after carmustine infusion.

9. Regulatory Status and Future Perspectives

9.1. Current Investigational Status of VI-0609

VI-0609 is currently an investigational drug and has not received marketing approval from the U.S. Food and Drug Administration (FDA) or other international regulatory authorities.[1] Its development is in Phase 2, with the NCT06915246 clinical trial actively evaluating its safety and tolerability.[1] While the individual components of the BEAM regimen, including carmustine (as BiCNU), etoposide, cytarabine, and melphalan, are FDA-approved drugs, their use in the specific context of VI-0609 replacing BiCNU within BEAM is considered new and unproven from a regulatory standpoint for the VI-0609 formulation itself.[7]

The regulatory pathway for VI-0609 might benefit from the extensive existing knowledge on carmustine. As a reformulation of an approved drug, VI-0609 could potentially follow a more streamlined regulatory process, such as the FDA's 505(b)(2) pathway. This pathway allows applicants to reference existing data on the safety and efficacy of an approved drug (in this case, BiCNU), provided that bridging studies (like NCT06915246) can demonstrate comparable efficacy and/or an improved safety profile for the new formulation. The current Phase 2 trial's emphasis on infusion-related toxicity endpoints aligns well with a strategy aimed at demonstrating a key safety advantage over the reference product.

9.2. VIVUS's Expanded Access Policy

According to VIVUS's stated policy, the company is not currently making its unapproved investigational drugs, which would include VI-0609, available on an expanded access (compassionate use) basis.[10] Should VIVUS decide to consider expanded access requests in the future, such requests would be evaluated on a case-by-case basis.[10]

9.3. Potential Impact on Lymphoma Treatment Paradigms

If the clinical development program, particularly the Phase 2 trial NCT06915246, successfully demonstrates that VI-0609 offers a significantly improved safety profile (especially concerning infusion-related toxicities) and comparable efficacy to BiCNU, it has the potential to become the preferred formulation of carmustine within conditioning regimens like BEAM.[1] Such an outcome could lead to several tangible benefits in clinical practice:

• Enhanced patient comfort and reduced distress during the administration of an otherwise arduous chemotherapy component.
• Potentially shorter infusion times, leading to greater convenience for patients and improved efficiency for healthcare facilities.
• Reduced need for medical interventions and supportive care to manage infusion-related adverse events, possibly translating into cost savings.

VIVUS has expressed optimism that VI-0609 may deliver improved outcomes for patients with refractory or relapsed Hodgkin or Non-Hodgkin lymphoma.[1] However, these forward-looking statements are appropriately tempered by acknowledgments of the inherent risks and uncertainties in pharmaceutical research and development. These include the possibility of not meeting anticipated clinical endpoints, delays in trial completion or regulatory submissions, and ultimately, the challenge of securing regulatory approval and successful market launch.[1]

The market adoption of VI-0609, if approved, will likely be influenced by pharmacoeconomic considerations in addition to clinical data. As BiCNU is an older drug with available generic versions, it represents a relatively low-cost component of the BEAM regimen. VI-0609, as a newly developed, proprietary formulation, would likely be introduced at a premium price. Therefore, demonstrating a clear clinical and economic advantage—such as a reduction in hospitalization days due to toxicity, decreased need for rescue medications, or substantial improvements in patient-reported outcomes and quality of life—will be crucial for justifying its value to healthcare providers and payers and ensuring widespread adoption.

10. Conclusion

VI-0609, an investigational ethanol-free formulation of carmustine developed by VIVUS LLC, represents a targeted effort to improve the therapeutic index of a long-established chemotherapeutic agent. Its current evaluation in a Phase 2 clinical trial (NCT06915246) as part of the BEAM conditioning regimen for patients with relapsed or refractory lymphoma undergoing autologous hematopoietic cell transplantation is a critical step in determining its future clinical role. The primary rationale for VI-0609's development is the mitigation of ethanol-related infusion toxicities associated with the conventional BiCNU formulation, which are a known source of patient discomfort and clinical management challenges.

The successful demonstration of reduced infusion-related adverse events, potentially coupled with the ability to shorten infusion times without compromising the systemic efficacy of carmustine, would mark a significant patient-centric advancement. This focus on improving tolerability and the patient experience during intensive cancer therapy aligns with an increasingly important paradigm in oncology drug development, where enhancements in quality of life are recognized as valuable clinical outcomes alongside traditional efficacy measures.

While VI-0609 holds the promise of alleviating specific solvent-related side effects, it is anticipated that the broader systemic toxicity profile inherent to carmustine, including delayed myelosuppression and pulmonary toxicity, will persist. Therefore, vigilant monitoring and adherence to established precautions for carmustine therapy will remain paramount. The ultimate success of VI-0609 will hinge on the demonstration of a clear net clinical benefit: a superior safety profile for infusion-related events compared to BiCNU, assurance that the alternative solvent system (likely propylene glycol) does not introduce new, offsetting safety concerns, and confirmation that the anti-lymphoma efficacy of carmustine is preserved. The data emerging from the ongoing Phase 2 trial will be instrumental in shaping the future therapeutic landscape for carmustine-containing conditioning regimens and will determine if VI-0609 can indeed offer a safer, more tolerable option for this vulnerable patient population.

Works cited

1. VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma - GlobeNewswire, accessed May 19, 2025, https://www.globenewswire.com/news-release/2025/04/14/3060953/0/en/VIVUS-Announces-Enrollment-of-First-Patient-in-Phase-2-Clinical-Trial-Assessing-Ethanol-Free-Carmustine-as-a-Component-of-High-Dose-Chemotherssapy-Prior-to-Transplant-in-Patients-wit.html
2. VI-0609 - Drug Targets, Indications, Patents - Synapse, accessed May 19, 2025, https://synapse.patsnap.com/drug/c92264c81108428b969d6808a3b2c711
3. VIVUS Announces Enrollment of First Patient in ... - GlobeNewswire, accessed May 19, 2025, https://www.globenewswire.com/news-release/2025/04/14/3060953/0/en/VIVUS-Announces-Enrollment-of-First-Patient-in-Phase-2-Clinical-Trial-Assessing-Ethanol-Free-Carmustine-as-a-Component-of-High-Dose-Chemotherapy-Prior-to-Transplant-in-Patients-wit.html
4. VIVUS - Products, Competitors, Financials, Employees, Headquarters Locations, accessed May 19, 2025, https://www.cbinsights.com/company/vivus
5. VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma | Morningstar, accessed May 19, 2025, https://www.morningstar.com/news/globe-newswire/9421130/vivus-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-assessing-ethanol-free-carmustine-as-a-component-of-high-dose-chemotherapy-prior-to-transplant-in-patients-with-hodgkin-or-non-hodgkin-lymphoma
6. VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as, accessed May 19, 2025, https://www.vivus.com/pdf/press-releases/2025-04-14%5EVIVUS%5EVIVUS_Announces_Enrollment_of_1st_Patient_Phase_2_Trial_Assessing_Ethanol_Free_Carmustine_as_Component_of_High_Dose_Chemotherapy_Prior_to_Transplant_in_Patients_with_Hodgkin_or_Non_Hodgkin_Lym.pdf
7. A drug, carmustine (VI-0609), in combination with ethanol or propylene glycol, to treat lymphoma before autologous (your own cells) blood or marrow transplant (BMT) - Jason Carter Clinical Trial Search and Support, accessed May 19, 2025, https://www.ctsearchsupport.org/clinical-trials/a-study-of-carmustine-with-and-without-ethanol-in-subjects-with-lymphoma
8. www.accessdata.fda.gov, accessed May 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017422s038lbl.pdf
9. BiCNU - accessdata.fda.gov, accessed May 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017422s037lbl.pdf
10. VIVUS Product Pipleline, accessed May 19, 2025, https://www.vivus.com/our-products-and-pipeline/our-pipeline/
11. DRUG NAME: Carmustine - BC Cancer, accessed May 19, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Carmustine%20monograph.pdf
12. Carmustine - LiverTox - NCBI Bookshelf, accessed May 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548307/
13. Carmustine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 19, 2025, https://go.drugbank.com/drugs/DB00262
14. Carmustine (intravenous route) - Mayo Clinic, accessed May 19, 2025, https://www.mayoclinic.org/drugs-supplements/carmustine-intravenous-route/description/drg-20067151
15. A Study of Carmustine With and Without Ethanol in Subjects With ..., accessed May 19, 2025, https://www.cancer.gov/clinicaltrials/NCI-2025-02742
16. A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma - NCI, accessed May 19, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-02742
17. 405-Autologous conditioning BEAM (carmustine etoposide ... - eviQ, accessed May 19, 2025, https://www.eviq.org.au/haematology-and-bmt/blood-and-marrow-transplant/autologous/405-autologous-conditioning-beam-carmustine-etopo
18. BEAM Conditioning Is Well Tolerated and Yields Similar Survival in Obese and Non-Obese Patients with Lymphoma: No Requirement for Weight-Based Dose Modifications, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5332312/
19. Carmustine Monograph for Professionals - Drugs.com, accessed May 19, 2025, https://www.drugs.com/monograph/carmustine.html
20. Carmustine: MedlinePlus Drug Information, accessed May 19, 2025, https://medlineplus.gov/druginfo/meds/a682060.html
21. Carmustine, BCNU injection - Cleveland Clinic, accessed May 19, 2025, https://my.clevelandclinic.org/health/drugs/18564-carmustine-bcnu-injection
22. Carmustine Intravenous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 19, 2025, https://www.webmd.com/drugs/2/drug-19920/carmustine-intravenous/details
23. BiCNU, Gliadel (carmustine) dosing, indications, interactions, adverse effects, and more, accessed May 19, 2025, https://reference.medscape.com/drug/bicnu-gliadel-carmustine-342194